bovnews41m
BMY’s Latest Twist: What’s Fueling the Unexpected Shifts in Bristol-Myers Squibb Co’s Stock Price?
On Friday, Bristol-Myers Squibb Co (BMY) stock saw a modest uptick, ending the day at $50.91 which represents a slight increase of $0.79 or 1.58% from the prior close of $50.12. The stock opened at ...
Investopedia3d
Bristol Myers Squibb Stock Rises After Schizophrenia Drug Gets FDA Approval
Matthias Balk / picture alliance via Getty Images Bristol Myers Squibb's drug to treat schizophrenia was approved for use by the Food and Drug Administration. The pharmaceutical firm called ...
Business Insider3d
Bristol-Myers Squibb: Hold Rating Amid New Schizophrenia Drug Launch and Patent Expiries
Analyst Evan Seigerman from BMO Capital maintained a Hold rating on Bristol-Myers Squibb (BMY – Research Report) and increased the price target to $53.00 from $48.00. Evan Seigerman has given ...
Morningstar3d
Bristol-Myers Squibb Co
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Yahoo Finance2d
Bristol-Myers Squibb Company (BMY)
PRINCETON, N.J., September 27, 2024--U.S. FDA Approves Bristol Myers Squibb’s COBENFY, a First-In-Class Muscarinic Agonist for the Treatment of Schizophrenia in Adults Business Wire • 6 hours ...